U.S. Medical
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
This site is intended for U.S. Healthcare Professionals.
To report an adverse event or product quality complaint, call 1-877-TAKEDA-7 (1-877-825-3327)
Not an actual patient.
VWD presents with a broad range of bleeding phenotypes, and this contributes to difficulty in diagnosis and potential delays of 15 years or more from the onset of bleeding symptoms to receiving diagnosis and treatment.3,4
There are an estimated 23 to 110 cases of VWD per million people.5 Population-based estimates are higher, ranging from 0.6-1.3% of people.
There are 3 types of VWD.2,6 Type 1 VWD, which accounts for ~75% of cases, is characterized by a reduced amount of VWF and with mild or moderate bleeding episodes.
Type 2 VWD, which accounts for ~25% of cases, is characterized by qualitative defects of VWF that impair its function.2,6 This is associated with bleeding episodes that can range from mild to severe.
Type 3 VWD accounts for <5% of cases, and is characterized by a near complete quantitative deficiency of VWF in plasma and with severe bleeding episodes.2,6
The 2021 guideline recommendations from the American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and World Federation of Hemophilia (WFH) has outlined the criteria for confirmatory diagnosis and differential diagnosis of VWD subtypes.4
For individuals with low probability of VWD, such as those seen in primary care, a validated bleeding assessment tool (BAT) is recommended as an initial screening to see who needs specific blood tests.4 For those with intermediate risk (those who have been referred to a hematologist because of bleeding history) and for those with high risk (those with an affected first-degree relative), specific blood testing for VWD is recommended:
Specific blood tests, followed by additional testing if necessary, can rule out VWD or confirm the diagnosis and subtype of VWD.4
Von Willebrand Factor (VWF) mediates platelet adhesion and stabilizes FVIII.1,7
In primary hemostasis, VWF mediates platelet adhesion to damaged vascular subendothelium by binding to exposed collagen and platelet receptors such as GPIbα and αIIbβ.1,7
In secondary hemostasis, VWF stabilizes FVIII in circulation by the formation of non-covalently bound VWF:FVIII complexes, thus preventing the rapid clearance of FVIII and increasing the half-life of FVIII.1,7
The quantitative or qualitative defects in VWF that are seen in VWD can lead to an inability to form platelet plugs (primary hemostasis) and to protect FVIII from proteolytic degradation (secondary reduction in FVIII levels), therefore leading to symptoms of bleeding.1,8
VWD can manifest in a diverse range of bleeding symptoms:5,8,9,10
Following diagnosis of VWD and its type, the guidelines outline best practices for a variety of VWD manifestations.11 This may range from prophylaxis for patients with a history of severe bleeds, on-demand treatment recommendations for other patients, and perioperative precautions for all patients.
Recommended Content
You may also be interested in these topics:
Clinical Trials
Find information about Takeda-sponsored clinical trials. See how our patient-driven philosophy fuels our scientific discovery as we strive to address important medical and scientific questions.
Scientific Congresses in Hematology
Plan to attend upcoming congresses in hematology, or explore resources, data, and presentations from past events to stay informed.
Medical Inquiries
U.S. Medical Affairs at Takeda is here to provide you with access to scientific information. Let us know how we can help.
This site is intended only for healthcare professionals registered to practice in the U.S. and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. The information is not intended as medical advice and may be incomplete. This resource may include information that has not been approved by the U.S. Food and Drug Administration (FDA). Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional.
Choose an option that describes you:
By clicking on this option, I certify that I am a U.S. healthcare professional.
Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.